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N (%) N (%) N (%)
Male 78 (55.7) 20 (57.1) 58 (55.2)
Diagnosis
ALL 81 (57.9) 18 (51.4) 63 (60.0)
AML 54 (38.6) 16 (45.7) 38 (36.2)
MDS 5 (3.6) 1 (2.9) 4 (3.8)
Disease Stage
Early 49 (35.0) 14 (40.0) 35 (33.3)
Intermediate 81 (57.9) 19 (54.3) 62 (59.1)
Advanced 10 (7.1) 2 (5.7) 8 (7.6)
Ethnicity
Hispanic White 65 (46.4) 11 (31.4) 54 (51.4)
Non-Hispanic White 56 (40.0) 20 (57.1) 36 (34.3)
Asian 13 (9.3) 2 (5.7) 11 (10.5)
African-American 6 (4.3) 2 (5.7) 4 (3.8)
Donor Type
Sibling 78 (55.7) 23 (65.7) 55 (52.4)
Unrelated 62 (44.3) 12 (34.3) 50 (47.6)
Donor Age
0-19 Years 74 (52.9) 23 (65.7) 51 (48.6)
20-39 Years 43 (30.7) 8 (22.9) 35 (33.3)
40-55 Years 23 (16.4) 4 (11.4) 19 (18.1)
Graft Source
Bone Marrow 77 (55.0) 18 (51.4) 59 (56.2)
Peripheral Blood 63 (45.0) 17 (48.6) 46 (43.8)
Year of Transplantation
1997-2002 69 (49.3) 18 (51.4) 51 (48.6)
2003-2007 71 (50.7) 17 (48.6) 54 (51.4)
Female-to-Male Graft
Yes 32 (22.9) 8 (22.9) 24 (22.9)
No 108 (77.1) 27 (77.1) 81 (77.1)
Conditioning Regimen
*TBI + Etoposide 74 (52.9) 17 (48.6) 57 (54.3)
*TBI + Cy 45 (32.1) 12 (34.3) 33 (31.4)
Busulfan + Cy 21 (15.0) 6 (17.1) 15 (14.3)
GVHD Prophylaxis
Cyclosporine + MTX 81 (57.9) 24 (68.6) 57 (54.3)
Tacrolimus (+other) 51 (36.4) 11 (31.4) 40 (38.1)
Cyclosporine + MMF 8 (5.7) 0 8 (7.6)
* TBI indicates total body irradiation, delivered in fractionated doses in 116/119 cases; HSCT, hematopoietic stem cell transplantation; CMV,
cytomegalovirus; ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; MDS, myelodysplastic syndromes; GVHD, graft-ver-
sus-host disease; Cy, cyclophosphamide; MTX, methotrexate; MMF mycophenolate mofetil.
In ‘‘Donor and Recipient CMV Serostatus and Outcome of Pediatric Allogeneic HSCT for Acute
Leukemia in the Era of CMV-Preemptive Therapy’’ (Behrendt et al, Biol Blood Marrow Transplant
2009:15(1): 54-60), there were incomplete row labels in Table 1. The corrected Table 1 is as follows:
649
